Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Despite entering its maturation phase, the recombinant protein sector will continue to drive the growth of medical biotechnology over the next six years.
China is a growing biotech player whose main competitive edge lies in low development costs. But will inexperienced money men and a disinterested pharmaceutical industry hold it back? Sabine Louët investigates.